|
23.04.2010
Unlike the majority of other industries, German biotechnology has actually grown during the crisis. In 2009, the number of employees exceeded the 30,000 mark for the first time. These are the central results of the company survey carried out at the beginning of 2010 by the information platform biotechnologie.de on behalf of the Federal Ministry of Education and Research (BMBF).
|
|
20.05.2009
The economic crisis hasn't yet reached the German biotechnology sector. These are the results of the biotechnology company survey 2009, which was conducted by biotechnologie.de on behalf of the German Federal Ministry for Education and Research (BMBF).
|
|
19.05.2008
In 2007, German biotechnology underwent distinctly moderate growth: For the first time, turnover climbed to over two billion euros (+14%), and expenditure on research and development (+8%) reached one billion euros – also a first.
|
|
24.10.2007
Every year, extensive surveys give us a wealth of facts and figures about the biotech sector in Germany: How has it developed? How much revenue have the companies generated? In this overview we have compiled the most interesting facts and figures to help you get to grips with the economic and financial situation of the core biotech companies in Germany.
|
|
31.05.2007
The biotech industry in Germany reached new levels of maturity in 2006: when compared to the previous year, both the number of employees and the revenues generated by the sector increased markedly. This is the central finding of the most recent survey of biotechnology companies, conducted in spring 2007 by the information portal biotechnologie.de on behalf of the German Federal Ministry of Education and Research (BMBF). The data, which was gathered according to the guidelines laid out by the Organisation for Economic Cooperation and Development (OECD), provides a comprehensive overview of the economic situation of the German biotech landscape.
|
|
30.04.2007
Innovative activity in the German biotech industry has clearly been undergoing a resurgence in the past few years. This is at least the picture painted by the latest patent atlas, which the German Patent & Trademark Office (DPMA) presented in mid-February in Munich. The statistics in the atlas give a regional overview of all patent applications sent to the German and European patent offices from 2000 to 2005 from inventors resident in Germany. However, biotechnology was only taken into account through a limited selection of patents, in particular those that relate to microorganisms and enzymes. Within these fields, the number of applications between 1995 and 2005 more than doubled. A view of the inventors’ locations shows a clear regional concentration: Around every tenth biotech patent originated from Munich and every eighth from Berlin.
|
|
31.05.2006
Just two decades ago, biotechnology in Germany was taking its first developmental steps in the marketplace. Today, it is firmly established as a commercial branch. This is the picture emerging from the recent national biotechnology survey, taking in biotech companies of all sizes from across Germany, and carried out by biotechnologie.de on behalf of the Federal Ministry for Education and Research (BMBF). For the first time in this sector, the data complies with statistical standards as set by the Organization for Economic Cooperation and Development (OECD), allowing for a reliable and internationally comparable description of the German biotech landscape.
|
